Overall, this research has clarified how GA works to increase LDLR accumulation and LDL uptake in HepG2 cells, laying a new theoretical foundation for the development of NAFLD drugs. The gene discussed is LDLR; the disease is metabolic dysfunction-associated steatotic liver disease.